Concert Pharmaceuticals Stock Fundamentals
| CNCEDelisted Stock | USD 8.37 0.01 0.12% |
Concert Pharmaceuticals fundamentals help investors to digest information that contributes to Concert Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Concert Stock. The fundamental analysis module provides a way to measure Concert Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Concert Pharmaceuticals stock.
Concert |
Concert Pharmaceuticals Company Current Valuation Analysis
Concert Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Concert Pharmaceuticals Current Valuation | 86.63 M |
Most of Concert Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Concert Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Concert Pharmaceuticals has a Current Valuation of 86.63 M. This is 99.4% lower than that of the Biotechnology sector and 98.14% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.48% higher than that of the company.
Concert Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Concert Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Concert Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Concert Pharmaceuticals competition to find correlations between indicators driving Concert Pharmaceuticals's intrinsic value. More Info.Concert Pharmaceuticals is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Concert Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Concert Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Concert Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Concert Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Concert Pharmaceuticals by comparing valuation metrics of similar companies.Concert Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Concert Fundamentals
| Return On Equity | -1.09 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (2.88) % | |||
| Current Valuation | 86.63 M | |||
| Shares Outstanding | 48.02 M | |||
| Shares Owned By Insiders | 3.77 % | |||
| Shares Owned By Institutions | 77.05 % | |||
| Number Of Shares Shorted | 1.08 M | |||
| Price To Earning | 3.08 X | |||
| Price To Book | 1.67 X | |||
| Price To Sales | 7.05 X | |||
| Revenue | 32.58 K | |||
| Gross Profit | (54.98 M) | |||
| EBITDA | 1.4 M | |||
| Net Income | (80.05 K) | |||
| Cash And Equivalents | 154.57 M | |||
| Cash Per Share | 3.22 X | |||
| Total Debt | 14.51 M | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 10.03 X | |||
| Book Value Per Share | 2.78 X | |||
| Cash Flow From Operations | (55.15 M) | |||
| Short Ratio | 0.26 X | |||
| Earnings Per Share | (3.17) X | |||
| Target Price | 11.67 | |||
| Number Of Employees | 64 | |||
| Beta | 0.49 | |||
| Market Capitalization | 401.95 M | |||
| Total Asset | 165.32 M | |||
| Retained Earnings | (210.05 M) | |||
| Working Capital | 137.48 M | |||
| Current Asset | 144.11 M | |||
| Current Liabilities | 6.63 M | |||
| Z Score | 14.8 | |||
| Net Asset | 165.32 M |
About Concert Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Concert Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Concert Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Concert Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. Concert Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 64 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Concert Stock
If you are still planning to invest in Concert Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Concert Pharmaceuticals' history and understand the potential risks before investing.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |